Literature DB >> 14624311

In vivo priming of natural killer T cells by dendritic cells pulsed with hepatoma-derived acid-eluted substances.

Ritsuko Ishii1, Masumi Shimizu, Yohko Nakagawa, Kazuo Shimizu, Shigeo Tanaka, Hidemi Takahashi.   

Abstract

Many murine tumor cells express not only individual haplotype-matched class I MHC molecules, but also species-specific CD1d molecules. The former class I MHC molecules generally present internally synthesized tumor-derived peptide antigens to highly specific CD8(+) cytotoxic T lymphocytes (CTLs) in acquired immunity. In contrast, the latter CD1d molecules may present tumor-associated glycolipid antigens to broadly crossreactive natural killer T (NKT) cells, which might correlate with controlling tumor metastasis. Here, we showed that murine hepatoma cell line Hepa1-6-derived acid-eluted substances might contain both D(b) class I MHC-restricted antigens and CD1d-restricted substances, which could sensitize not only syngeneic bone marrow-derived DCs (BM-DCs), but also allogeneic BM-DCs expressing haplotype-mismatched class I MHC and species-specific CD1d molecules. To our surprise, intravenous (i.v.) immunization of C57BL/6 mice with the former syngeneic BM-DCs carrying acid-eluted materials primed both CD4(-)CD8(-) and CD8(+) NKT cells in the spleen, whereas immunization with the latter allogeneic BM-DCs loaded the tumor-derived substances primed CD4(-)CD8(-), but not CD8(+) NKT cells. The findings shown in the present study will open a new area for cancer immunotherapy using allogeneic DCs and tumor-derived acid-eluted substances.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624311     DOI: 10.1007/s00262-003-0453-0

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  2 in total

1.  Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells.

Authors:  Hirotomo Harimoto; Masumi Shimizu; Yohko Nakagawa; Katsuhisa Nakatsuka; Ayako Wakabayashi; Choitsu Sakamoto; Hidemi Takahashi
Journal:  Immunol Cell Biol       Date:  2013-09-10       Impact factor: 5.126

2.  Suppression of murine tumour growth through CD8+ cytotoxic T lymphocytes via activated DEC-205+ dendritic cells by sequential administration of α-galactosylceramide in vivo.

Authors:  Hideki Kogo; Masumi Shimizu; Yasuyuki Negishi; Eiji Uchida; Hidemi Takahashi
Journal:  Immunology       Date:  2017-04-18       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.